Novo Nordisk has secured European Commission approval for a new 7.2 mg once‑weekly maintenance dose of its obesity drug Wegovy (semaglutide injection). The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued on December 12 2025 and allows doctors to prescribe the higher dose as three 2.4 mg injections given in a single sitting, once a week, rather than a single 2.4 mg injection three times per week.
Clinical studies that underpinned the approval showed an average 21 % body‑weight loss over 18 months (72 weeks). The new dose offers a more potent option for patients who have not achieved their desired weight loss on the 2.4 mg maintenance dose, providing a step‑up that can be tailored to individual needs. The approval also broadens Wegovy’s therapeutic profile, as the drug is already indicated for weight management, cardiovascular risk reduction, heart‑failure with preserved ejection fraction, and osteoarthritis‑related knee pain in obese patients.
The regulatory milestone positions Novo Nordisk more strongly against competitors such as Eli Lilly’s tirzepatide (Zepbound). The higher dose could help the company capture a larger share of the growing global obesity‑drug market, which is projected to expand substantially in the coming years. Novo Nordisk has also applied for a single‑dose pen for the 7.2 mg formulation, which could further improve patient convenience and adherence if approved.
Management highlighted the strategic importance of the new dose. Executive vice president Emil Kongshøj Larsen said, “The new dose gives healthcare professionals even more flexibility to tailor treatment and help people with obesity achieve their weight loss and health goals.” Executive vice president Ludovic Helfgott added, “This positive opinion means a new Wegovy option, delivering weight loss of 20.7 %, could be available for people with obesity early in the new year, pending the European Commission’s final approval.”
The approval follows a similar UK approval and precedes pending applications in the United States and other major markets. By expanding its dosing options, Novo Nordisk aims to maintain its leadership in the GLP‑1 therapy space while addressing the increasing demand for more effective weight‑loss solutions.
The 7.2 mg dose is expected to strengthen Novo Nordisk’s competitive position, support future revenue growth, and reinforce its commitment to delivering innovative obesity treatments across the EU.
revised_sentiment_rating
}
importance
high
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.